Track Tonix Pharmaceuticals Holding Corp. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tonix Pharmaceuticals Holding Corp. TNXP · Stock Open Tonix Pharmaceuticals Holding Corp. in new tab

3.01 USD
P/E
0.05
EPS
-13.06
P/B
0.33
ROE
-84.06
Beta
1.90
Target Price
34.00 USD
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp.

🧾 Earnings Recap – Q3 2026

Tonix shares fell 5.3% after earnings, suggesting investors were not reassured by early launch momentum. While TONMYA sales grew, the launch remains in an early stage, and the transcript points to gross-to-net fluctuations and a newly filed generic challenge as key risks.

  • TONMYA generated approximately $15 million in third-quarter net sales, up 37% quarter over quarter; management said payer agreements contributed and gross-to-net adjustments were more favorable than expected.
  • Prescriptions rose 28% quarter over quarter to 16,375, including 17% growth in new prescriptions and 56% growth in refills. The expanded 150-rep sales force began field work on September 1, with increases across several prescription and writer metrics since then.
  • Coverage reached approximately 53% of U.S. covered lives. The company also reported improving prescription approval rates among commercially insured patients and fewer bridge prescriptions.
  • Gross-to-net adjustments are expected to fluctuate early in the launch. Separately, Dr. Reddy’s filed an ANDA with a Paragraph IV patent certification for TONMYA; Tonix said it intends to defend its intellectual property.
  • Tonix is advancing Phase II programs in major depressive disorder, Lyme disease prevention, and kidney transplant rejection.
📅
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
P/E0.05
EPS-13.06
Book Value13.24
Price to Book0.33
Debt/Equity0.63
% Insiders0.160%
Growth
Revenue Growth4.24%
Estimates
Forward P/E-0.63
Forward EPS-6.82
Target Mean Price34.00

DCF valuation

Model fair value for Tonix Pharmaceuticals Holding Corp. (TNXP)
Result
Sign in to run the valuation for TNXP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 34.00 USD (low 18.00, high 64.00) · as of 10 Nov 2026
Low 18.00
Mean 34.00
High 64.00
Price 3.01
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Tonix Pharmaceuticals Holding Corp. Logo Tonix Pharmaceuticals Holding Corp. Analysis (TNXP)

United States Health Care Official Website Stock

Is Tonix Pharmaceuticals Holding Corp. a good investment? Tonix Pharmaceuticals Holding Corp. (TNXP) is currently trading at 3.01 USD. Market analysts have a consensus price target of 34.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 0.05. This relatively low multiple may signal that Tonix Pharmaceuticals Holding Corp. is undervalued compared to historical market norms.

Earnings Schedule: Tonix Pharmaceuticals Holding Corp. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -6.82.

Investor FAQ

Does Tonix Pharmaceuticals Holding Corp. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tonix Pharmaceuticals Holding Corp.?

Tonix Pharmaceuticals Holding Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -13.06.

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Exchange Ticker
NGM (Sweden) TNXP
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 1, 2013 1:20
March 17, 2017 1:10
Nov. 28, 2018 1:10
Nov. 1, 2019 1:10
May 17, 2022 1:32
May 10, 2023 0.16
June 10, 2024 1:32
Feb. 5, 2025 1:100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion